-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Orthopoxvirus
- Others
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Virus Protease
- Antiviral intermediates
RSV-IN-1
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/861139-16-4.gif)
| Category | Respiratory syncytial Virus (RSV) |
| CAS | 861139-16-4 |
| Description | RSV-IN-1 is a human respiratory syncytical virus (hRSV) inhibitor with IC50 value of 0.11 μM. |
Product Information
| Synonyms | N-(2-hydroxyethyl)-4-methoxy-N-methyl-3-(6-methyl-[1,2,4]triazolo[3,4-a]phthalazin-3-yl)benzenesulfonamide |
| IUPAC Name | N-(2-hydroxyethyl)-4-methoxy-N-methyl-3-(6-methyl-[1,2,4]triazolo[3,4-a]phthalazin-3-yl)benzenesulfonamide |
| Molecular Weight | 427.48 |
| Molecular Formula | C20H21N5O4S |
| Canonical SMILES | CC1=NN2C(=NN=C2C3=C(C=CC(=C3)S(=O)(=O)N(C)CCO)OC)C4=CC=CC=C14 |
| InChI | InChI=1S/C20H21N5O4S/c1-13-15-6-4-5-7-16(15)19-21-22-20(25(19)23-13)17-12-14(8-9-18(17)29-3)30(27,28)24(2)10-11-26/h4-9,12,26H,10-11H2,1-3H3 |
| InChIKey | RKHSOIYWKCMPHF-UHFFFAOYSA-N |
| Purity | 99.95% |
| Density | 1.4±0.1 g/cm3 |
| Solubility | In vitro: 10 mM in DMSO |
| Appearance | White to off-white (Solid) |
| Storage | Powder: -20°C: 3 years 4°C: 2 years In solvent: -80°C: 6 months -20°C: 1 month |
| Complexity | 689 |
| Exact Mass | 427.13142534 |
| Index Of Refraction | 1.685 |
| In Vitro | The concentration of P13 that reduces the number of RSV plaques in HEp-2 cells by 50% (IC50) is 0.11 μM. The concentration of P13 that reduces the viability of HEp-2 by 50% (CC50) is 310 μM. Note that some cytotoxicity of P13 observed at 500 μM might be due to DMSO solvent. Hence, the selective index (CC50/IC50) values is 2818 for P13. Note that even at the relatively high concentrations P13 does not completely block the development of RSV plaques. These escape plaques are of smaller size and of non-syncytial phenotype as compared to plaques formed in the absence of inhibitor. . |
| Target | IC50: 0.11μM (hRSV) |
| XLogP3-AA | 1.5 |
